The Global Fund's Regional Artemisinin-resistance Initiative (RAI) was launched in 2013 in response to the emergence of drug-resistant malaria in the Greater Mekong region, first noted in Cambodia and Thailand and later Myanmar, Laos and Viet Nam. RAI has supported countries to purchase and distribute commodities such as insecticide-treated nets, rapid diagnostic tests that don't require a laboratory or medical expertise, and quality-assured drugs, which together have yielded a sharp drop in malaria deaths.
The RAI as been expanded with a second phase, the RAI2-Elimination (RAI2E) programme, which is a $ 243 million regional grant to accelerate elimination of P. falciparum malaria in the Greater Mekong Sub-region over a three-year period (2018-2020).
The RAI2E supports increased malaria service coverage for remote populations in border areas and other at-risk populations, as well as case management through health volunteers and strengthening of national surveillance systems.